Publications

5677 Results

Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis

Authors
NJ McCleary;S Zhang;C Ma;F Ou;T Bainter;A Venook;D Niedzwiecki;H-J Lenz;F Innocenti;B O'Neil;H Hochster;J Atkins;R Goldberg;K Ng;R Mayer;CD Blanke;E O'Reilly;C Fuchs;J Meyerhardt
Journal / Conference
Journal of Geriatric Oncology May;13(4):469-479
Year
2022
Research Committee(s)
Gastrointestinal
PMID
PMID35105521
PMC
PMC9058225
Study Number(s)
CTSU/C80405

Associations of Inflammatory Biomarkers with Survival Among Patients with Stage III Colon Cancer (CALGB/SWOG 80702 [Alliance])

Authors
E Cheng;Q Shi;A Shields;N Rifai;E Feliciano;J Meyers;A Nixon;A Shegrill;K Guthrie;F Couture;P Kuebler;J Bendell;P Kumar;D Lewis;B Tan;E O'Reilly;J Brown;P Philip;B Caan;J Meyerhardt
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer

Authors
E Gonzalez-Kozlova;H-H Huang;M Redman;R Herbst;S Gettinger;L Bazhenova;H Xie;M Patel;K Nie;J Harris;K Argueta;D Del Valle;S Kim-Schulze;S Gnjatic
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I

Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial

Authors
E Parra;J Zhang;M Redman;R Lazcano;M Piubelli;C Laberiano Fernandez;R Pandurengan;S Zhang;H Chen;G Manyam;D Duose;J Zhang;G Al-Atrash;R Herbst;K Kannan;E Gonzalez-Kozlova;S Gnjatic;I Wistuba;S Gettinger;L Bazhenova;J Lee;J Zhang;C Haymaker
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I

Immune Gene Expression Signatures associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial

Authors
D Duose;J Zhang;M Redman;B Zhang;R Luthra;G Al-Atrash;R Herbst;E Gonzalez-Kozlova;S Gnjatic;I Wistuba;S Gettinger;L Bazhenova;J Lee;J Zhang
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I

SWOG S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy

Authors
A VanderWalde;J Moon;K Kendra;N Khushalani;F Collichio;J Sosman;A Ikeguchi;A Victor;T-G Truong;B Chmielowski;D Portnoy;M Wu;K Grossmann;A Ribas
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), plenary, oral
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
S1616

Circulating tumor DNA dynamics on front line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: a biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial

Authors
K Raghav;F-S Ou;A Venook;F Innocenti;R Sun;H-J Lenz;S Kopetz
Journal / Conference
ASCO Gastrointestinal Cancer Symposium (Jan 20-22, 2022, San Francisco, CA), poster session, Abst #193
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Alliance A031902 (CASPAR): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)

Authors
A Rao;C Ryan;J VanderWheele;G Heller;L Lewis;A Tan;C Watt;R Chen;M Kohli;P Barata;B Gartrell;R Grubb;A Dueck;Y Wen;M Morris
Journal / Conference
J Clin Oncol 40, 2022 (suppl 6; abstr TPS194); ASCO Genitourinary (GU) Cancers Symposium 2022 (Feb 17-19, 2022, San Francisco, CA)
Year
2022
Research Committee(s)
Genitourinary

Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials

Authors
J Gelfond;B Hernandez;M Goros;J Ibrahim;M Chen;W Sun;M Liss;R Leach;I Thompson;D Ankerst
Journal / Conference
BMC Urology Mar 26;22(1):45. doi: 10.1186/s12894-022-00986-w.
Year
2022
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID35351104
PMC
PMC8966358
Study Number(s)
S0000

Survey of US Medical Oncologists’ Practices and Beliefs regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy

Authors
K Koo;A Pasternak;NL Henry;V Sahai;D Hertz
Journal / Conference
JCO Oncology Practice Jun;18(6):e958-e965
Year
2022
PMID
PMID35239419
PMC
PMC9191302